Responding to "National Weight Management Year," Contributing to Healthy China! Raynovent's RAY1225 Injection Phase III Clinical Study Successfully Achieves Full Subject Enrollment Milestone

Guangdong Raynovent Biotech Co., Ltd. ("Raynovent") is pleased to announce that RAY1225 Injection, its independently developed globally innovative GLP-1/GIP dual receptor agonist for the treatment of obese or overweight adult patients in China, has recently completed full subject enrollment in its Phase III registrational clinical study with high quality! This significant milestone not only marks a core achievement in this pivotal study but also represents the company's concrete action in actively responding to the National Health Commission's deployment of the "National Weight Management Year" initiative and implementing the "Healthy China" strategy.

PART 01: Exceptional Execution Power—Full Enrollment Completed Within One Month After First Subject

This Phase III clinical study successfully enrolled its first subject in June of this year, demonstrating rapid and efficient progress. Concurrently, the Phase II clinical study design and results made their debut on the global academic stage—presented as a poster at the 84th Scientific Sessions of the American Diabetes Association (ADA) held in Chicago, USA—showcasing China's cutting-edge exploration in innovative weight loss and glucose-lowering therapies to the international academic community and receiving positive attention.

RAY1225 Injection is the world's first biweekly GLP-1/GIP dual agonist to enter Phase III clinical trials, with safety profiles leading in its class. The Raynovent project team, adhering to efficient and rigorous execution standards, completed full subject enrollment ahead of schedule within one month after the first enrollment, as planned. This fully demonstrates the professional collaboration among investigators, clinical centers, and the company team, and also reflects the urgent demand from the patient population for innovative and safe weight management solutions.

PART 02: Dual-Target Biweekly Weapon—Responding to National Weight Management Strategy

Obesity and related metabolic diseases currently represent a major public health threat to national health. At the national level, this issue has received high attention, with 2024 explicitly designated as the "National Weight Management Year," aiming to establish a comprehensive weight management support environment for all citizens, enhance scientific weight loss capabilities, and address the significant public health challenge of overweight/obesity.

As Raynovent's core pipeline product in the metabolic disease field, RAY1225 demonstrates significant advantages through its innovative dual agonist mechanism of GLP-1 and GIP. In Phase II studies, with a 9mg biweekly dosing regimen, it achieved an average weight loss of 15.05% after 24 weeks, with 95% of subjects achieving weight loss ≥5%. It also showed comprehensive potential for significant improvement in other metabolic indicators such as blood lipids and uric acid, while maintaining favorable safety profiles—injecting robust technological power into the "Chinese Weight Loss Solution."

PART 03: Tribute to Outstanding Teams—Continuing High-Quality Clinical Development

We extend our heartfelt gratitude to all study participants, investigators, partners, and the company's project team for their hard work and outstanding contributions!

Raynovent will continue to closely monitor study progress and advance the subsequent clinical development of RAY1225 with high quality. We look forward to the early revelation of study data, facilitating RAY1225's early benefit to Chinese patients, providing an innovative "weapon" for scientific weight management, and contributing solid technological strength to advancing the "Healthy China" initiative and enhancing national health and well-being!